Keen Vision Acquisition Corp. (KVAC) has issued an unsecured promissory note to extend the deadline for completing its initial business combination, now pushed to July 27, 2026. The company remains focused on acquiring Medera, a Cayman Islands biotech firm specializing in pre-clinical human disease modeling and drug discovery. KVAC’s value proposition centers on leveraging sponsor expertise and ESG-focused investment criteria to drive growth post-merger in biotechnology, consumer goods, and agriculture sectors. However, liquidity constraints outside the trust account stress the need for timely completion of the merger. Key upcoming milestones include finalizing a replacement merger agreement and securing shareholder approvals.